Glioblastoma blood flow measured with stable xenon CT indicates tumor necrosis, vascularity, and brain invasion.
暂无分享,去创建一个
R. Zwiggelaar | M. Papadopoulos | Chris Jones | S. Saadoun | B. Bell | L. Bridges | S. Zacharoulis | M. Crocker | A. Jury | Samiwel Thomas | S. Thomas
[1] P. Black,et al. Angiogenesis in Brain Tumors , 2013, Cancer Treatment and Research.
[2] Kim Mouridsen,et al. T1- and T*2-Dominant Extravasation Correction in DSC-MRI: Part I—Theoretical Considerations and Implications for Assessment of Tumor Hemodynamic Properties , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[3] N. Brünner,et al. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids , 2011, Journal of Neuro-Oncology.
[4] M. Papadopoulos,et al. Serum Angiogenic Profile of Patients with Glioblastoma Identifies Distinct Tumor Subtypes and Shows That TIMP-1 Is a Prognostic Factor , 2010 .
[5] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[6] A. Alavi,et al. Molecular imaging (PET) of brain tumors. , 2009, Neuroimaging clinics of North America.
[7] M. Law,et al. Magnetic resonance perfusion and permeability imaging in brain tumors. , 2009, Neuroimaging clinics of North America.
[8] R. Fimmers,et al. Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients , 2009, Clinical Cancer Research.
[9] T E Yankeelov,et al. A theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation , 2009, Physics in medicine and biology.
[10] K. Khalili,et al. Molecular mechanisms of necrosis in glioblastoma: The role of glutamate excitotoxicity , 2009, Cancer biology & therapy.
[11] Dorothee P. Auer,et al. Quantitative imaging biomarkers in neuro-oncology , 2009, Nature Reviews Clinical Oncology.
[12] P. Wen,et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. , 2009, Cancer research.
[13] A. Unterberg,et al. The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. , 2009, Anti-cancer agents in medicinal chemistry.
[14] Tracy T Batchelor,et al. Angiogenesis as a therapeutic target in malignant gliomas. , 2009, The oncologist.
[15] V. Amberger-Murphy. Hypoxia helps glioma to fight therapy. , 2009, Current cancer drug targets.
[16] R. Jensen,et al. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target , 2009, Journal of Neuro-Oncology.
[17] Tracy T Batchelor,et al. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas , 2008, Current opinion in neurology.
[18] C. Gladson,et al. New molecular targets in angiogenic vessels of glioblastoma tumours , 2008, Expert Reviews in Molecular Medicine.
[19] M. J. van den Bent,et al. Molecular targeted therapies and chemotherapy in malignant gliomas , 2007, Current opinion in oncology.
[20] A. Gregory Sorensen,et al. Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.
[21] Alan Koretsky,et al. Technological advances in MRI measurement of brain perfusion , 2005, Journal of magnetic resonance imaging : JMRI.
[22] M. Matsuda,et al. Threshold of regional cerebral blood flow for infarction in patients with acute cerebral ischemia. , 2005, Journal of neuroradiology. Journal de neuroradiologie.
[23] Daniel J Brat,et al. Genetic Markers in Glioblastoma: Prognostic Significance and Future Therapeutic Implications: On: Impact of Genotype Morphology on the Prognosis of Glioblastoma. Schmidt MC Antweiler S, Urban N, et al. J Neuropathol Exp Neurol 2002;61:321–328. , 2003, Advances in anatomic pathology.
[24] R. Selway,et al. Posterior lumbar interbody fusion for revision disc surgery: review of 50 cases in which carbon fiber cages were implanted. , 2001, Journal of neurosurgery.
[25] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[26] A. Ruifrok,et al. Quantification of histochemical staining by color deconvolution. , 2001, Analytical and quantitative cytology and histology.
[27] P. Black,et al. Anti-angiogenic Treatment Strategies for Malignant Brain Tumors , 2000, Journal of Neuro-Oncology.
[28] R. Roemer,et al. Cerebral bloodflow in and around spontaneous malignant gliomas. , 1996, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[29] S. Kety,et al. THE NITROUS OXIDE METHOD FOR THE QUANTITATIVE DETERMINATION OF CEREBRAL BLOOD FLOW IN MAN: THEORY, PROCEDURE AND NORMAL VALUES. , 1948, The Journal of clinical investigation.
[30] A. Chakravarti,et al. Molecular profiling in glioblastoma: Prelude to personalized treatment , 2009, Current oncology reports.
[31] S. Niclou,et al. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. , 2009, Expert opinion on therapeutic targets.
[32] E. Fainardi,et al. Cerebral blood flow thresholds predicting new hypoattenuation areas due to macrovascular ischemia during the acute phase of severe and complicated aneurysmal subarachnoid hemorrhage. A preliminary study. , 2008, Acta neurochirurgica. Supplement.
[33] Tracy T Batchelor,et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.
[34] M. Westphal,et al. Invasion as limitation to anti-angiogenic glioma therapy. , 2003, Acta neurochirurgica. Supplement.
[35] D. Van Roost,et al. Changes of Cerebral Blood Flow Following Dexamethasone Treatment in Brain Tumour Patients. A Xe/CT Study , 2001, Acta Neurochirurgica.
[36] S. Takeuchi,et al. Haemodynamic Evaluation of Cerebral Gliomas Using XeCT , 1998, Acta Neurochirurgica.
[37] J. Palmer,et al. Statistical modelling in analysis of prognosis in glioblastoma multiforme: a study of clinical variables and Ki-67 index. , 1991, British journal of neurosurgery.
[38] D. Gur,et al. Stable xenon CT/CBF imaging: laboratory and clinical experience. , 1987, Advances and technical standards in neurosurgery.